Top 10 Gainers: INSM +40% . MEET +19% . BIOC +18% . LIVE +16% . RARE +13% . EXA +13% . ETRM +13% . GBR +13% . PLUG +11% . CCIH +11% . Top 10 Losers: DOM -29% . ECYT -16% . CLRX -15% . CBPO -12% . VRS -12
Gainers: INSM +29% . ETRM +15% . MEET +13% . ZLCS +13% . LIVE +8% . ADBE +9% . RGSE +8% . APD +6% . Losers: ECYT -15% . LZB -11% . GDP -8% . NGL -6% . GWPH -5% . Post your comment!
June 18 (Reuters) - EnteroMedics Inc's shares jumped about 37 percent in premarket trading on Wednesday, a day after an advisory panel to the U.S. Food and Drug Administration voted in favor of the...
The FDA's Gastroenterology and Urology Devices Panel votes 8:1 in favor of the safety of EnteroMedics ' ( ETRM ) Maestro VBLOC Therapy system for the treatment of obesity, but votes 4:5 on the issue of reasonable assurance of efficacy
The NASDAQ halts trading in EnteroMedics ( ETRM ) pending news from an Ad Comm meeting to discuss whether or not to recommend regulatory approval for the company's Maestro System for treating morbid obesity. Post your comment!
ACHN +18% . NFEC +24% . ECOM +16% . NWBO +15% . VICR +14% . Top 10 Losers: EDN -13% . KPTI -12% . DWA -11% . VTUS -10% . OTC:INVT -10% . LAYN -10% . BIOA -10% . ETRM -9% . KONA -9% . ARSD -9% . 1 comment!
By Ernest Marmer : Enteromedics ( ETRM ) awaits an FDA review on Tuesday June 17th for its obesity device ..... and which any obesity therapy looks to have significant impact on ETRM 's Maestro/VBLOC system came in from the ReCharge study having
By Ernest Marmer : EnteroMedics ( ETRM ) is developing a vagus-nerve stimulator ..... for the US market. In recent years, ETRM has conducted two Phase III trials ..... Phase-III trials' results and trial design ETRM compared its Maestro vagal stimulator
By Scott Matusow : Written by Scott Matusow. Coming up on June 10th, 2014, Orexigen Therapeutics ( OREX ) expects a Food and Drug Administration (FDA) decision concerning its weight loss drug, NB32 (Contrave). Contrave was initially rejected by the FDA due to a single issue cardiovascular safety ...
By Scott Matusow : Written by Scott Matusow. The prediction of the FDA approving Contrave is an easy one. If Orexigen ( OREX ) has followed the agreed protocols in the SPA and the company has not deviated from the agreement, the FDA is bound to issue an approval. The FDA decision for Contrave is ...